Japan Pioneers Decentralized Clinical Trials in Oncology to Overcome Geographic Barriers
Japan is advancing decentralized clinical trials (DCTs) in oncology to address geographic barriers and improve access for patients with rare cancers or low-frequency genetic mutations.
Adjuvant Alectinib Confirmed as New Standard of Care in ALK+ NSCLC with Favorable Safety Profile
Updated safety data from the ALINA trial reinforce adjuvant alectinib's role as a standard treatment for ALK-positive non-small cell lung cancer (NSCLC).
© Copyright 2025. All Rights Reserved by MedPath